(Q79415846)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

title

Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Liu JM

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Wang LS

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Huang MH

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Hsu WH

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Yen SH

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Shiau CY

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Li AF

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Tiu CM

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Tseng SW

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Huang BS

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

publication date

1 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

502-509

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

Thymic epithelial tumors can develop along two different pathogenetic pathways

22 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Thymoma and thymic carcinoma: an update of the WHO Classification 2004.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Recurrent genetic aberrations in thymoma and thymic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Chromosome 6 suffers frequent and multiple aberrations in thymoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Chemotherapy for advanced thymoma. Preliminary results of an intergroup study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Chemotherapy of invasive thymoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Treatment and prognosis of primary thymic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

A multidisciplinary approach to therapy for unresectable malignant thymoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Treatment of invasive thymoma with single-agent ifosfamide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Thymic carcinoma with overexpression of mutated KIT and the response to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Radiosensitization of uterine cancer cell lines by cytotoxic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Prognostic implications of the expression of erbB2, topoisomerase II alpha and thymidylate synthase in metastatic gastric cancer after fluorouracil-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Gene expression analysis of human thymoma correlates with tumor stage

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Protein expression and gene amplification of epidermal growth factor receptor in thymomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22404

7 January 2021

Identifiers

DOI

10.1002/CNCR.22404

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17154178%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference